FDA Approves AbbVie's VYALEV for 24-Hour Treatment of Advanced Parkinson's Disease

AbbVie announced that the U.S. FDA has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating motor fluctuations in adults with advanced Parkinson’s disease (PD). Robert A. Hauser, M.D., MBA, Professor of Neurology and Director of the Parkinson’s and Movement Disorder Center at the University of South Florida, highlighted that this new, non-surgical regimen provides continuous delivery of levodopa morning, day and night.

Publish Date: 17-10-2024 Source: AbbVie

Parkinson’s disease, a chronic and progressive disorder of the central nervous system, falls under the category of motor system disorders. This condition stems from the loss of cells in the substantia nigra region of the brain, which are responsible for producing dopamine, a crucial neurotransmitter facilitating communication within the brain. Dopamine ensures the smooth and coordinated operation of the body’s muscles and movement. Consequently, the depletion of dopamine results in uncontrolled neuronal activity, leaving individuals incapable of managing or directing their movements. The symptoms of Parkinson’s disease typically manifest gradually and intensify over time. These symptoms can encompass tremors or shaking, challenges in maintaining balance and walking, stiffness in the limbs and torso, and a general slowing down of movement, medically known as bradykinesia. Patients often struggle with basic activities like walking, speaking, and completing simple tasks. Typically, symptoms become noticeable when there is damage to 60% to 80% of the dopamine-producing cells. Parkinson’s disease affects both genders almost equally, with no significant variations based on social, ethnic, economic, or geographical factors.

Globally, approximately 10 million people are living with Parkinson’s disease.

However, the current Parkinson’s Disease treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (ND0612, Safinamide, ADS-5102, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Parkinson’s Disease treatment. The key companies in the advanced development stage are NeuroDerm Ltd., Zambon SpA, Adamas Pharmaceuticals, Inc., etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Parkinson’s Disease to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2023 to 2033.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.